Key Clinical Message: Crigler-Najjar syndrome type 2 should be suspected in any young patient presenting with isolated indirect hyperbilirubinemia where all other common etiologies have been excluded. It is a relatively benign condition that responds to phenobarbitone.

Abstract: Crigler-Najjar syndrome (CNS) type 2 is an inborn cause of isolated indirect hyperbilirubinemia characterized by a partial deficiency of the enzyme uridine 5'-diphosphate-glucuronosyltransferase (UGT) responsible for bilirubin conjugation. Typically, this condition is diagnosed based on clinical manifestations, supplemented by enzyme analysis if feasible, and exhibits a significant response to phenobarbitone, known for its enzyme-inducing properties. In this case, we present a young male patient who had experienced recurrent isolated indirect hyperbilirubinemia since early childhood, with negative results in the hemolytic workup. The patient exhibited a UGT1A1 gene defect and demonstrated a highly favorable response to phenobarbitone treatment. The purpose of this report is to raise awareness among physicians about this benign condition and underscore the importance of avoiding unnecessary investigations.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643321PMC
http://dx.doi.org/10.1002/ccr3.8176DOI Listing

Publication Analysis

Top Keywords

crigler-najjar syndrome
12
isolated indirect
12
indirect hyperbilirubinemia
12
syndrome type
8
benign condition
8
response phenobarbitone
8
rare case
4
case crigler-najjar
4
type case
4
case report
4

Similar Publications

Crigler-Najjar syndrome is an ultra-rare monogenic recessive liver disease caused by gene mutations. Complete UGT1A1 deficiency results in severe unconjugated hyperbilirubinemia in newborns that, if not treated, may lead to brain damage and death. Treatment is based on intensive phototherapy, but its efficacy decreases with age, rendering liver transplantation the only curative option.

View Article and Find Full Text PDF

Therapeutic Options for Crigler-Najjar Syndrome: A Scoping Review.

Int J Mol Sci

October 2024

Pediatric Clinic, Department of Medicine and Surgery, University Hospital of Parma, 43126 Parma, Italy.

Article Synopsis
  • Crigler-Najjar Syndrome (CNS) is a rare genetic disorder that leads to severe jaundice due to impaired processing of bilirubin, with two forms: CNS type 1 (more severe) and CNS type 2 (milder).
  • The management of CNS1 is aggressive, often requiring liver transplantation as the only definitive treatment, while CNS2 can be managed with medications like phenobarbital.
  • New therapies, including gene therapy and autologous hepatocyte transplantation, are emerging as potential alternatives to surgery, aiming to enhance treatment effectiveness and improve life quality for CNS patients.
View Article and Find Full Text PDF

Analysis of UGT1A1 genotype-phenotype correlation in Chinese patients with gilbert and crigler-Najjar II syndrome.

Eur J Med Genet

October 2024

Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China. Electronic address:

Article Synopsis
  • The study examined UGT1A1 gene variants in 310 Chinese patients with Gilbert syndrome (GS) and Crigler-Najjar syndrome (CNS-II) to understand genotype-phenotype correlations.
  • A total of 21 different UGT1A1 variants were identified, including nine that were previously unknown, with a distinct variant pattern compared to Western populations.
  • The research found significant differences in serum total bilirubin and triglyceride levels among various genotypes, indicating how specific UGT1A1 variants affect clinical outcomes in patients.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!